The short answer
Grapefruit seed extract has not been shown to raise lemborexant levels or cause this combination’s toxicity. Do not treat seed extract as equivalent to grapefruit juice; have the exact product checked before use.
What this answer covers
Grapefruit seed extract; distinct from fruit, juice and fruit extract. Product authenticity matters.
- Supplement or preparation
- Grapefruit Seed Extract
- Medication ingredient
- lemborexant
Seed extract is a separate preparation
A product labeled grapefruit seed extract is not the same exposure as grapefruit fruit or juice. The inspected sources do not establish an authentic seed-extract interaction with lemborexant. Missing direct evidence does not establish safety.
A frequently cited report involved adulteration
Investigators examined products sold as grapefruit seed extract after a warfarin adverse report. The analyzed products contained a synthetic preservative and no authentic seed extract. Laboratory enzyme inhibition in that report cannot be assigned to genuine seed constituents.
Lemborexant’s metabolism still matters
Lemborexant is sensitive to CYP3A inhibitors, and its label restricts strong and moderate inhibitors. Studies with known drug inhibitors do not prove that an unspecified seed product belongs to either category.
Check ingredients rather than inventing a gap
Show the exact label and ingredients to the pharmacist or prescriber. No verified protective spacing interval or seed-extract-specific dose adjustment was established. Report unexpected excessive drowsiness or next-day impairment.
Evidence and practical considerations
Side effects & toxicity
No authentic grapefruit seed extract-lemborexant clinical evidence. Adulterated commercial products and in-vitro preservative effects cannot validate seed-specific increased absorption, blood levels or toxicity; juice evidence is not interchangeable.
- Exact scope
- Grapefruit seed extract; distinct from fruit, juice and fruit extract. Product authenticity matters. with Lemborexant2272403 IN, oral DAYVIGO tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed lemborexant
Avoid strong/moderate CYP3A inhibitors and inducers; St John’s wort explicitly named. Other insomnia medicines not recommended. Additive CNS depression and complex sleep behaviors.
How this applies: Exact lemborexant RxCUI 2272403 IN, with stated salt/formulation/route bridge.
No measured seed-extract, CBD, kava or generic valerian combination risk.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy adults in phase1 open-label studies.
Inhibitors increased exposure approximately3.7–4fold; rifampin reduced exposure over90%. No severe or serious adverse events reported.
How this applies: Other drugs, not supplements. Expected somnolence15minutes–9hours was not recorded as an adverse event unless more pronounced than expected. Lemborexant’s null effect on midazolam is the reverse interaction direction.
Other drugs, not supplements. Expected somnolence15minutes–9hours was not recorded as an adverse event unless more pronounced than expected. Lemborexant’s null effect on midazolam is the reverse interaction direction.
Source 3: Original case report and analytical laboratory study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: A reported warfarin-treated couple and three analyzed commercial products.
Analyzed products contained benzethonium chloride; no authentic seed extract detected. Preservative inhibited CYP3A4/2C9 in vitro.
How this applies: Warfarin report and adulterated products, not authentic seed extract or lemborexant; enzyme assay cannot establish exact clinical risk.
Warfarin report and adulterated products, not authentic seed extract or lemborexant; enzyme assay cannot establish exact clinical risk.
Research assessment: · Open full citations ↗
Absorption & effectiveness
No authentic grapefruit seed extract-lemborexant clinical evidence. Adulterated commercial products and in-vitro preservative effects cannot validate seed-specific increased absorption, blood levels or toxicity; juice evidence is not interchangeable.
- Exact scope
- Grapefruit seed extract; distinct from fruit, juice and fruit extract. Product authenticity matters. with Lemborexant2272403 IN, oral DAYVIGO tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed lemborexant
Avoid strong/moderate CYP3A inhibitors and inducers; St John’s wort explicitly named. Other insomnia medicines not recommended. Additive CNS depression and complex sleep behaviors.
How this applies: Exact lemborexant RxCUI 2272403 IN, with stated salt/formulation/route bridge.
No measured seed-extract, CBD, kava or generic valerian combination risk.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy adults in phase1 open-label studies.
Inhibitors increased exposure approximately3.7–4fold; rifampin reduced exposure over90%. No severe or serious adverse events reported.
How this applies: Other drugs, not supplements. Expected somnolence15minutes–9hours was not recorded as an adverse event unless more pronounced than expected. Lemborexant’s null effect on midazolam is the reverse interaction direction.
Other drugs, not supplements. Expected somnolence15minutes–9hours was not recorded as an adverse event unless more pronounced than expected. Lemborexant’s null effect on midazolam is the reverse interaction direction.
Source 3: Original case report and analytical laboratory study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: A reported warfarin-treated couple and three analyzed commercial products.
Analyzed products contained benzethonium chloride; no authentic seed extract detected. Preservative inhibited CYP3A4/2C9 in vitro.
How this applies: Warfarin report and adulterated products, not authentic seed extract or lemborexant; enzyme assay cannot establish exact clinical risk.
Warfarin report and adulterated products, not authentic seed extract or lemborexant; enzyme assay cannot establish exact clinical risk.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact lemborexant article with formulation-specific evidence and uncertainty. |
Article revision: f655f093c359ac23
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.